Renner, Kathrin and Seilbeck, Anton and Kauer, Nathalie and Ugele, Ines and Siska, Peter J. and Brummer, Christina and Bruss, Christina and Decking, Sonja-Maria and Fante, Matthias and Schmidt, Astrid and Hammon, Kathrin and Singer, Katrin and Klobuch, Sebastian and Thomas, Simone and Gottfried, Eva and Peter, Katrin and Kreutz, Marina (2018) Combined Metabolic Targeting With Metformin and the NSAIDs Diflunisal and Diclofenac Induces Apoptosis in Acute Myeloid Leukemia Cells. FRONTIERS IN PHARMACOLOGY, 9: 1258. ISSN 1663-9812,
Full text not available from this repository. (Request a copy)Abstract
The accelerated metabolism of tumor cells, inevitable for maintaining high proliferation rates, is an emerging target for tumor therapy. Increased glucose and lipid metabolism as well as mitochondrial activity have been shown in solid tumors but also in leukemic cells. As tumor cells are able to escape the blockade of one metabolic pathway by a compensatory increase in other pathways, treatment strategies simultaneously targeting metabolism at different sites are currently developed. However, the number of clinically applicable anti-metabolic drugs is still limited. Here, we analyzed the impact of the anti-diabetic drug metformin alone or in combination with two non-steroidal anti-inflammatory drugs (NSAIDs) diclofenac and diflunisal on acute myeloid leukemia (AML) cell lines and primary patient blasts. Diclofenac but not diflunisal reduced lactate secretion in different AML cell lines (THP-1, U937, and KG-1) and both drugs increased respiration at low concentrations. Despite these metabolic effects, both NSAIDs showed a limited effect on tumor cell proliferation and viability up to a concentration of 0.2 mM. In higher concentrations of 0.4-0.8 mM diflunisal alone exerted a clear effect on proliferation of AML cell lines and blocked respiration. Single treatment with the anti-diabetic drug metformin blocked mitochondrial respiration, but proliferation and viability were not affected. However, combining all three drugs exerted a strong cytostatic and cytotoxic effect on THP-1 cells. Comparable to the results obtained with THP-1 cells, the combination of all three drugs significantly reduced proliferation of primary leukemic blasts and induced apoptosis. Furthermore, NSAIDs supported the effect of low dose chemotherapy with cytarabine and reduced proliferation of primary AML blasts. Taken together we show that low concentrations of metformin and the two NSAIDs diclofenac and diflunisal exert a synergistic inhibitory effect on AML proliferation and induce apoptosis most likely by blocking tumor cell metabolism. Our results underline the feasibility of applying anti-metabolic drugs for AML therapy.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | SIGNALING PATHWAY; INHIBITION; TUMORS; LINE; CHEMOTHERAPY; SENSITIVITY; COMBINATION; SUPPRESSION; CANCER; DRUGS; metabolism; acute myeloid leukemia; AML; diclofenac; diflunisal; metformin; apoptosis |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 10 Oct 2019 07:01 |
| Last Modified: | 10 Oct 2019 07:01 |
| URI: | https://pred.uni-regensburg.de/id/eprint/13559 |
Actions (login required)
 |
View Item |
